140 related articles for article (PubMed ID: 15044783)
1. Polio endgame. Wanted: drug for a disappearing disease.
Enserink M
Science; 2004 Mar; 303(5666):1971. PubMed ID: 15044783
[No Abstract] [Full Text] [Related]
2. A case for developing antiviral drugs against polio.
Collett MS; Neyts J; Modlin JF
Antiviral Res; 2008 Sep; 79(3):179-87. PubMed ID: 18513807
[TBL] [Abstract][Full Text] [Related]
3. Identification and Analysis of Antiviral Compounds Against Poliovirus.
Leyssen P; Franco D; Tijsma A; Lacroix C; De Palma A; Neyts J
Methods Mol Biol; 2016; 1387():325-38. PubMed ID: 26983743
[TBL] [Abstract][Full Text] [Related]
4. Antiviral therapeutic intervention in poliomyelitis-like syndrome.
Arya SC
Brain Dev; 1999 Dec; 21(8):567; author reply 568. PubMed ID: 10598062
[No Abstract] [Full Text] [Related]
5. R75761, a lead compound for the development of antiviral drugs in late stage poliomyelitis eradication strategies and beyond.
Thys B; De Palma AM; Neyts J; Andries K; Vrijsen R; Rombaut B
Antiviral Res; 2008 Jun; 78(3):278-81. PubMed ID: 18294707
[TBL] [Abstract][Full Text] [Related]
6. Infectious diseases. Report concludes polio drugs are needed--after disease is eradicated.
Couzin J
Science; 2006 Mar; 311(5767):1539. PubMed ID: 16543427
[No Abstract] [Full Text] [Related]
7. Biotech bonanza.
Stipp D
Fortune; 1999 Nov; 140(9):333-4. PubMed ID: 10623111
[No Abstract] [Full Text] [Related]
8. Frustrated by regulatory delays at FDA, biotech companies warm to user fees.
Gershon D
Nature; 1992 Aug; 358(6388):616. PubMed ID: 1495553
[No Abstract] [Full Text] [Related]
9. Spinning the wheel on ImClone.
Varchaver N
Fortune; 2003 Apr; 147(8):123-5. PubMed ID: 12728651
[No Abstract] [Full Text] [Related]
10. Biotech jostles with pharma for slice of HIV market.
Katsnelson A
Nat Biotechnol; 2006 Jan; 24(1):3-4. PubMed ID: 16404375
[No Abstract] [Full Text] [Related]
11. Clearance of Immunodeficiency-associated Vaccine-derived Poliovirus Infection With Pocapavir.
Copelyn J; Hincks JR; Wilmshurst JM; Petersen W; Howard W; Jallow S; Moonsamy S; Seakamela L; Suchard M; Collett MS; Eley B
Pediatr Infect Dis J; 2020 May; 39(5):435-437. PubMed ID: 32150007
[TBL] [Abstract][Full Text] [Related]
12. This Dutchman is flying.
Watson N
Fortune; 2003 Jun; 147(13):89-90. PubMed ID: 12827720
[No Abstract] [Full Text] [Related]
13. A testing approach based on tiny doses still awaits big results.
Coombs A
Nat Med; 2008 Aug; 14(8):796. PubMed ID: 18685584
[No Abstract] [Full Text] [Related]
14. Western biotechs ponder follow-on possibilities.
Waltz E
Nat Biotechnol; 2008 Sep; 26(9):962-3. PubMed ID: 18779793
[No Abstract] [Full Text] [Related]
15. Bills target biosimilar drugs.
Wadman M
Nature; 2009 Mar; 458(7237):394-5. PubMed ID: 19325595
[No Abstract] [Full Text] [Related]
16. FDA launches priority vouchers for neglected-disease drugs.
Waltz E
Nat Biotechnol; 2008 Dec; 26(12):1315-6. PubMed ID: 19060849
[No Abstract] [Full Text] [Related]
17. Lucrative niches: how drugs for rare diseases became lifeline for companies.
Anand G
Wall St J (East Ed); 2005 Nov; ():A1, A18. PubMed ID: 16502531
[No Abstract] [Full Text] [Related]
18. Path to approval proves rocky for copycat biodrugs.
Wadman M
Nature; 2005 Nov; 438(7065):154-5. PubMed ID: 16281004
[No Abstract] [Full Text] [Related]
19. How changes in drug-safety regulations affect the way drug and biotech companies invest in innovation.
Reed SD; Califf RM; Schulman KA
Health Aff (Millwood); 2006; 25(5):1309-17. PubMed ID: 16966727
[TBL] [Abstract][Full Text] [Related]
20. The market for follow-on biologics: how will it evolve?
Grabowski H; Cockburn I; Long G
Health Aff (Millwood); 2006; 25(5):1291-301. PubMed ID: 16966725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
